EXTON, Pa.--(BUSINESS WIRE)-- Fibrocell Science, Inc. (OTCBB: FCSC), a biotechnology company focused on commercializing LAVIV, the first and only FDA-approved personalized cell therapy in aesthetic dermatology, and on developing innovative autologous cell therapies for additional aesthetic, medical and scientific applications, announced today that David Pernock, the Company’s Chairman and CEO, will host an investor conference call to discuss Fibrocell’s private placement financing and strategic collaboration with Intrexon Corporation on Wednesday, October 17, 2012 at 4:30 PM Eastern Time.
Fibrocell invites all interested parties to join the call by dialing 877-705-6003 for domestic participants and 201-493-6725 for international participants. The call will also be broadcast live over the Internet and can be accessed on the Investors section of the Company’s website at www.fibrocellscience.com.
A telephone replay will be available for two weeks following the call by dialing 877-870-5176 for domestic participants and 858-384-5517 for international participants. When prompted, please enter replay pin number 401789. For those who are not available to listen to the live webcast, the call will be archived for 90 days on Fibrocell’s website.
About Fibrocell Science, Inc.
Fibrocell Science, Inc. (OTCBB: FCSC) is an autologous cellular therapeutic company focused on the development of innovative products for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well as its innovative cellular processing technology and manufacturing excellence. For additional information, please visit www.fibrocellscience.com.
Source: Fibrocell Science, Inc.